Revolution Medicines, Inc. (NASDAQ: RVMD) disclosed that Stephen Michael Kelsey, Senior Advisor to the Chief Executive Officer, sold 27,160 shares of common stock on November 16, 2026. The transactions totaled approximately $4,559,209, with per-share prices ranging from $166.14 to $171.65. The sales were executed pursuant to a pre-arranged 10b5-1 trading plan that Kelsey adopted on August 17, 2026.
Prior to the sales, Kelsey exercised options to acquire 27,160 shares of common stock at $18.56 per share, for a total cost of $504,089. These options were fully vested. Following the transactions, Kelsey directly holds 286,307 shares of Revolution Medicines common stock, a position that includes 65,613 restricted stock units. In addition, he beneficially owns 108,640 derivative securities in the form of stock options.
The sale comes as Revolution Medicines' stock trades at $159.82, down 9.4% over the past week. Despite that recent pullback, the shares have delivered a 127% return over the past year, with a year-to-date gain exceeding 100%. According to InvestingPro analysis, Revolution Medicines appears undervalued at current levels, with the stock trading below its Fair Value.
In other recent developments, Revolution Medicines reported its first quarter of product revenue following the U.S. launch of RASONQUE, with net product sales reaching $197.6 million in the third quarter of 2026. The company recorded a net loss of $407.5 million due to increased spending on commercialization and late-stage development, yet investors focused on the rapid revenue growth. Additionally, the European Commission has approved RASONQUE for the treatment of metastatic pancreatic ductal adenocarcinoma, expanding its potential market.
Analyst firms have shown confidence in Revolution Medicines. H.C. Wainwright reiterated a Buy rating and set a price target of $350.00. Stifel also maintained a Buy rating, with a price target of $230.00, and noted the stock as an attractive buying opportunity below $200 per share. Stifel believes that the stock's potential upside depends on opportunities beyond pancreatic cancer. These developments highlight significant progress for Revolution Medicines in both the U.S. and European markets.